Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter–Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease

Author:

Kuck Karl-Heinz1,Tilz Roland Richard1,Deneke Thomas1,Hoffmann Boris A.1,Ventura Rodolfo1,Hansen Peter Steen1,Zarse Markus1,Hohnloser Stefan H.1,Kautzner Josef1,Willems Stephan1

Affiliation:

1. From the Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany (K.-H.K., R.R.T.); University Heart Center, University Hospital Bergmannsheil, Bochum, Germany (T.D.); University Heart Center, Department of Cardiology - Electrophysiology, Hamburg, Germany (B.A.H., R.V., S.W.); Department of Cardiology, Aarhus University Hospital, Denmark (P.S.H.); University of Witten-Herdecke, Germany (M.Z.); University Hospital Frankfurt, Germany (S.H.H.); and Institute for Clinical and Experimental...

Abstract

Background— The implantable cardioverter–defibrillator (ICD) is the standard therapy to prevent sudden cardiac death in patients with coronary artery disease and unstable ventricular tachyarrhythmias. The prospective multinational SMS (Substrate Modification Study) was designed to assess whether prophylactic ablation of the arrhythmogenic substrate reduces or prevents the recurrence of ventricular tachycardia/ventricular fibrillation in such patients. Methods and Results— Of 111 patients included in an intention-to-treat analysis, 54 were randomly assigned catheter ablation plus ICD implantation (ablation group: 68±8 years; 47 men), whereas 57 were assigned ICD implantation without catheter ablation (ICD-only group: 66±8 years; 46 men). Primary study end point was the time to first recurrence of ventricular tachycardia/ventricular fibrillation. ICD episodes were assessed and verified by an independent board. Patients were followed up for 2.3±1.1 years. The primary end point was reached by 25 ablation patients and 26 ICD-only patients. Two-year event-free survival was estimated at 49.0% (95% confidence interval, 33.3%–62.9%) in the former and 52.4% (36.7%–65.9%) in the latter groups. Comparison of episode incidence revealed no significant difference in the primary end point ( P =0.84). In an Andersen–Gill regression model with multiple end point recurrences, the difference between the study arms significantly favored catheter ablation for both the primary end point and all but one of the predefined subgroups of detected arrhythmia events. Conclusions— SMS failed to meet the primary end point of time to first ventricular tachycardia/ventricular fibrillation recurrence. However, catheter ablation did reduce the total number of ICD interventions during the duration of follow-up. Clinical Trial Registration— https://clinicaltrials.gov . Unique identifier: NCT00170287.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3